Patent 9321832 was granted and assigned to Domantis Limited on April, 2016 by the United States Patent and Trademark Office.
The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity.